- Home
- CYD vs TRVI Comparison
CYD vs TRVI Comparison
Compare CYD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYD | TRVI |
|---|---|---|
| Founded | 1951 | 2011 |
| Country | Singapore | United States |
| Employees | 8930 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CYD | TRVI |
|---|---|---|
| Price | $35.50 | $12.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $20.38 |
| AVG Volume (30 Days) | 112.3K | ★ 2.2M |
| Earning Date | 08-08-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 40.10 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $3,159,401,156.00 | N/A |
| Revenue This Year | $41.12 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $21.61 | ★ N/A |
| Revenue Growth | ★ 17.99 | N/A |
| 52 Week Low | $9.32 | $3.47 |
| 52 Week High | $42.60 | $14.39 |
Technical Indicators
Market Signals| Indicator | CYD | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 52.92 |
| Support Level | $35.32 | $12.60 |
| Resistance Level | $36.15 | $13.19 |
| Average True Range (ATR) | 0.97 | 0.67 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 30.42 | 33.87 |
Price Performance
Historical ComparisonAbout CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.